Clinical Trials
18 trialsNCT04704934 2026-05-27
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06346392 2026-05-27
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Active not recruiting
NCT07518147 2026-04-08
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT06793917 2025-07-20
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
Phase 3 Recruiting
NCT01839773 2024-07-25
DREAM
Daehwa Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT01924533 2024-03-22
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
AstraZeneca
Phase 3 Completed
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT02178956 2023-11-15
BRIGHTER
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT03019588 2023-03-30
MK-3475-063
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT02370498 2022-06-06
MK-3475-061
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02934464 2021-09-13
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3 Unknown
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT01248403 2020-01-29
AIO-STO-0111
Krankenhaus Nordwest
Phase 3 Completed
NCT01170663 2019-09-18
RAINBOW
Eli Lilly and Company
Phase 3 Completed
NCT03475615 2018-03-23
A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
Fudan University
Phase 3 Unknown
NCT00486954 2013-06-20
Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
GlaxoSmithKline
Phase 3 Completed
NCT01224652 2010-10-20
Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Korean Cancer Study Group
Phase 3 Unknown